A push to ramp up production of successful COVID-19 vaccines, continued demand for effective COVID-19 treatments, and an increased focus on other critical, non-COVID diseases are driving growth in the biotech industry – and against this backdrop, the author of today’s article highlights four particular biotech stocks that should see significant growth in the coming months. For these four stocks,…
Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product…
With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks…
When it comes to finding the best biotech stocks to buy, the author of today’s article acknowledges that it “can be tricky given that volatility often haunts the space.” Nonetheless, he proceeds to highlight three biotech stocks to watch – two of which are working on COVID-19 vaccines while the third may be worth a look even though the company…